Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) has formally entered into the Partnership Agreement to participate in the establishment of the Shanghai Biomedical Phase II Fund. The agreement was signed on 24 July 2026, confirming the principal terms previously outlined in the company’s 18 July 2026 announcement regarding the connected transaction.
The update signals the Board’s approval to advance the investment initiative, which is expected to strengthen Shanghai Pharma’s strategic presence in the biomedical sector. All other details disclosed in the earlier announcement remain unchanged.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments